- Home
- DSGN vs JGH Comparison
DSGN vs JGH Comparison
Compare DSGN & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- JGH
- Stock Information
- Founded
- DSGN 2017
- JGH 2014
- Country
- DSGN United States
- JGH United States
- Employees
- DSGN N/A
- JGH N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- JGH Investment Managers
- Sector
- DSGN Health Care
- JGH Finance
- Exchange
- DSGN Nasdaq
- JGH Nasdaq
- Market Cap
- DSGN 348.2M
- JGH 296.7M
- IPO Year
- DSGN 2021
- JGH N/A
- Fundamental
- Price
- DSGN $4.21
- JGH $12.93
- Analyst Decision
- DSGN Buy
- JGH
- Analyst Count
- DSGN 2
- JGH 0
- Target Price
- DSGN $8.00
- JGH N/A
- AVG Volume (30 Days)
- DSGN 156.4K
- JGH 73.9K
- Earning Date
- DSGN 03-10-2025
- JGH 01-01-0001
- Dividend Yield
- DSGN N/A
- JGH 9.85%
- EPS Growth
- DSGN N/A
- JGH N/A
- EPS
- DSGN N/A
- JGH N/A
- Revenue
- DSGN N/A
- JGH N/A
- Revenue This Year
- DSGN N/A
- JGH N/A
- Revenue Next Year
- DSGN N/A
- JGH N/A
- P/E Ratio
- DSGN N/A
- JGH N/A
- Revenue Growth
- DSGN N/A
- JGH N/A
- 52 Week Low
- DSGN $3.15
- JGH $10.36
- 52 Week High
- DSGN $7.77
- JGH $12.85
- Technical
- Relative Strength Index (RSI)
- DSGN 40.65
- JGH 42.03
- Support Level
- DSGN $4.06
- JGH $12.88
- Resistance Level
- DSGN $5.09
- JGH $13.08
- Average True Range (ATR)
- DSGN 0.38
- JGH 0.11
- MACD
- DSGN -0.08
- JGH 0.01
- Stochastic Oscillator
- DSGN 9.93
- JGH 53.85
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.